XCancer

Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related Tumors

Description:

Exploring the therapeutic value of a novel dual target molecular probe NI-FAPI-04 PET/CT with hypoxia and fibroblast activation related proteins in fibroblast activation related tumors. This study will lay the foundation for the further application of NI-FAPI-04 in tumor therapy and achieve the integration of molecular targeted probes for diagnosis, treatment, and efficacy monitoring.

Sponsor:

Peking Union Medical College Hospital

Phase:

Phase 1/2

Government Study Link:

NCT07822347 - Click here to see study on

ClinicalTrials.gov

NI-FAPI-04

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA
Inclusion
  • Bone marrow reserve: neutrophil count ≥ 1.5 × 109/L; platelet count ≥ 100 × 109/L; hemoglobin ≥ 90 g/L
  • Baseline \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging reveals high uptake lesions
Exclusion
  • Patients treated with isotopes such as strontium-89, samarium-153, rhenium 186, rhenium 188, radium-223, etc. within 6 months